One of the common diseases occurred in pregnant women is gestational diabetes mellitus (GDM). A report showed that the incidence of GDM was from the range of 2.4%-22.3% among pregnant women in the worldwide.
| Extraction and genotyping of DNA
Patients and control individuals were drawn 5 mL venous blood at the beginning of the study. The separation of the plasma content from blood specimens was first collected in tubes with anticoagulants and then centrifuged. The EDTA-treated whole blood was used to extract genomic DNA by the DNAzol BD reagent according to manufacturer's protocol (ThermoFisher, USA). PCR-RFLP was applied to detect genotyping of CDKN2A. The detection of CDKN2A genotyping was amplified through the forward and reverse primers. For CDKN2A, the forward and reverse primers were 5′-GGAGCCATTCTATCGTGAACA -3′ and 5′-CACCCGACTGGAAAACCTTAT -3′, respectively. The fragment lengths for CDKN2A were 475 bp. The PCR conditions were as following at 95°C for 5 minutes for initial denaturation, 35 cycles of 95°C for 30 seconds, 56°C for 30 seconds, and 72°C for 30 seconds for amplification, and finishing at 72°C for 4 minutes. The success rate of genotyping was 100%.
| Statistical methods
The means ± standard deviation expressed continuous variables, and N (%) of participants represented categorical variables in the study. The characteristic variances between patients with HBVrelated GDM and control individuals were calculated by the student t test or chi-square test. The association between CDKN2A and risk of HBV-related GDM was measured by conditional logistic regression analysis. The odds ratio (OR) and 95% confidence intervals (CIs)
were also shown in results. The reference group was defined as wide-type genotype of CDKN2A. The statistical analysis was processed by SPSS 17.0 package (SPSS Inc., Chicago, IL, USA).
| RE SULTS

| The association between HBV and gestational diabetes mellitus
The case-control study of 480 pregnant women diagnosed as HBVpositive and 530 HBV-negative ones was performed to study the association between HBV and gestational diabetes mellitus.
The average ages of patients and controls were 28.29 ± 3.54 and 27.00 ± 3.95 years, respectively. By student t test, patients with HBV were more likely to have higher BMI, fasting plasma glucose, and HOMA-IR, level of BUA and TC, when compared with the controls.
However, no obvious difference between two groups in the gestational age (P = 0.33), SBP (P = 0.31) and levels of TG (P = 2.11), LDL-c (P = 0.05), and HDL-c (P = 0.13). The details of these characteristics in HBV patients and controls were shown in Table 1 .
| The association between CDKN2A polymorphisms and gestational diabetes mellitus
Genotype and allele distributions of CDKN2A variants, rs10811661 and rs564398, among the HBV patients and the control individuals were displayed in Table 2 . For CDKN2A rs10811661, two genotypes, TT and TC, have differences in the genotype and frequencies in allele distribution between the HBV patients and the controls. The people with the CDKN2A rs564398 AA and AG genotypes have a significantly increased risk of HBV-related GDM in comparison with the GG genotype ( Table 2 ).
The CDKN2A polymorphisms were associated with age, BMI, fasting plasma glucose, and HOMA-IR for the risk of GDM (Table 3 and 4). We found CDKN2A polymorphisms were related to increased risk of GDM in HBV patients regardless of age.
The same exposure to environmental and lifestyle factors would not induce the development of the same diseases. It indicated the importance of genetic mutation in contribution to the development of diseases. The variations in a single nucleotide at a specific position in the genome were called as the single-nucleotide polymorphisms (SNPs). The variation is including to insert, miss, or replace a single nucleotide, which induces the polymorphism in the nucleic acid sequence. 13 These changes in gene polymorphisms will influence gene expression, and function of their translational products. 14, 15 In the study, a case-control investigation to study whether CDKN2A polymorphisms could influence the susceptibility to GDM in HBV patients was conducted. We found that the CDKN2A mutations were related to a greater risk of GDM.
The CDKN2A locus is on chromosome 9 p21.3. The dysfunction of liver in HBV patients was reported to associate with CDKN2A mutation. In addition, the polymorphisms in CDKN2A could decrease or eliminate detoxification of enzyme and increase the susceptibility to diseases, like GDM.
Accumulating studies have shown that CDKN2A polymorphisms presented in liver samples from HCC, chronic hepatitis, and liver cirrhosis patients. 16 The CDKN2A polymorphisms in above diseases were strongly associated with HBV (LIVINGSTON
S et al 2007). It was reported that HBV infection disrupted hepatic metabolic responses (SHI YX et al 2016)
. Thus, CDKN2A mutations suggested association between HBV and hepatic metabolic function. In addition, the association between CDKN2A polymorphisms and risk of GDM in this study indicated that CDKN2A polymorphisms were associated with the occurrence of GDM. 17 Currently, no report illustrated the relationship between polymorphisms of CDKN2A and risk of HBV-related GDM. This study investigated in a population with 480 GDM and 530 control individuals, and we found that CDKN2A polymorphisms were associated with the risk of HBV-related GDM.
In our study, we found that the CDKN2A mutations were correlated with the development of GDM in HBV patients. However, small sample size in our study was limited to our findings, which was better to further examine in large sample sizes. Moreover, there are still limitations in our study. First, samples were collected from one hospital, which might not represent the general population. Second, other genetic polymorphisms might contribute to develop gestational diabetes mellitus in HBV patients and CDKN2A gene polymorphisms. Third, the statistical error might occur because of small size sample. In conclusion, we suggest that the CDKN2A mutations are correlated with an increased risk of HBV-related GDM in the Chinese population. This finding was useful for studying the genetic features of HBV patients with GDM and developing more efficient preventive and therapeutic strategies.
